ME Therapeutics Holdings Inc. (CSE: METX) announced on October 9, 2026, that it has extended its option agreement with the National Research Council of Canada (NRC) to license a proprietary nanobody-based CD22 binder for use in Chimeric Antigen Receptor (CAR) therapy. The extension pushes the option's exercisable deadline to February 10, 2027, giving the Vancouver-based immuno-oncology company additional time to advance its in vivo CAR program. The announcement signals continued commitment to the CD22 asset as a potential cancer-fighting therapeutic, a development investors in the biotechnology sector may be watching closely.

Key Points

  • ME Therapeutics Holdings Inc. (CSE: METX, FSE: Q9T) is a Vancouver-based biotechnology company focused on immuno-oncology
  • The company has extended its option agreement with the NRC to license a CD22 nanobody-based binder for CAR therapy
  • The option to license the CD22 binder is now exercisable until February 10, 2027; all other terms remain unchanged
  • Investors may be watching whether METX exercises the option and advances the asset toward further preclinical or clinical development

ME Therapeutics Secures More Time on NRC's CD22 Nanobody Licence Option

ME Therapeutics announced it has reached an agreement to extend the deadline on its option to licence the National Research Council of Canada's proprietary nanobody-based CD22 binder. The CD22 target is relevant in certain blood cancers, and the nanobody format is designed for use in CAR therapy applications. The release states that all other terms of the original option agreement remain the same, with only the exercisable deadline now moved to February 10, 2027. The company did not disclose the financial terms of the extension in the announcement.

CD22 Nanobody's Role in ME Therapeutics' In Vivo CAR Program

According to the release, ME Therapeutics intends to continue developing the CD22 nanobody as part of its broader in vivo CAR program. The company describes itself as focused on developing therapeutics that reprogramme immune cells inside the body to reshape the tumour microenvironment and directly recognise and destroy cancer cells. The CD22 nanobody asset represents one component of this pipeline. The announcement does not provide updates on preclinical data, trial timelines, or partnership discussions related to this specific asset.

METX's Immuno-Oncology Focus and Strategic Context

ME Therapeutics is a publicly listed biotechnology company headquartered in Vancouver, British Columbia, operating in the immuno-oncology space. The company holds listings on both the Canadian Securities Exchange and the Frankfurt Stock Exchange. The extension of the NRC option agreement reflects the company's ongoing efforts to build and maintain its drug discovery pipeline. The immediate share price impact was not clear from available public information. The company did not disclose specific financial guidance or operational milestones alongside this announcement.